Amid heightened global trade tensions and economic uncertainty fueled by unexpected tariff announcements, investors are navigating a volatile market landscape. For those interested in exploring smaller or newer companies, penny stocks remain a relevant investment area despite their somewhat outdated moniker. These stocks can offer affordability and growth potential, particularly when paired with strong financials, making them worth watching for their potential to deliver impressive returns.

Top 10 Penny Stocks Globally

Name Share Price Market Cap Financial Health Rating CNMC Goldmine Holdings (Catalist:5TP) SGD0.365 SGD147.93M ★★★★★☆ Angler Gaming (NGM:ANGL) SEK3.45 SEK258.7M ★★★★★★ NEXG Berhad (KLSE:NEXG) MYR0.25 MYR653.81M ★★★★★★ DXN Holdings Bhd (KLSE:DXN) MYR0.495 MYR2.46B ★★★★★★ Lever Style (SEHK:1346) HK$1.07 HK$813.93M ★★★★★★ Next 15 Group (AIM:NFG) £2.51 £249.63M ★★★★☆☆ Warpaint London (AIM:W7L) £3.40 £274.68M ★★★★★★ Foresight Group Holdings (LSE:FSG) £3.14 £355.76M ★★★★★★ QinetiQ Group (LSE:QQ.) £3.774 £2.09B ★★★★★☆ EZZ Life Science Holdings (ASX:EZZ) A$1.31 A$68.87M ★★★★★★

Click here to see the full list of 5,658 stocks from our Global Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Fu Shou Yuan International Group

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Fu Shou Yuan International Group Limited, with a market cap of HK$8.68 billion, operates in the People’s Republic of China providing burial and funeral services through its subsidiaries.

Operations: The company's revenue is primarily derived from burial services (CN¥1.71 billion) and funeral services (CN¥339.19 million), with additional income from other services (CN¥37.44 million).

Market Cap: HK$8.68B

Fu Shou Yuan International Group, with a market cap of HK$8.68 billion, has shown mixed financial performance. Its short-term assets (CN¥3.6 billion) exceed both short and long-term liabilities, indicating solid liquidity. However, recent earnings have declined significantly due to decreased core business revenue and increased tax expenses, with net income dropping to CN¥373.13 million from CN¥791.24 million the previous year. Despite these challenges, the company maintains a strong cash position relative to its debt and has announced special dividends totaling approximately HKD 900 million for 2025 as part of its cash management strategy.

Unlock comprehensive insights into our analysis of Fu Shou Yuan International Group stock in this financial health report. Assess Fu Shou Yuan International Group's future earnings estimates with our detailed growth reports.

Story Continues

SEHK:1448 Revenue & Expenses Breakdown as at Apr 2025

Tong Ren Tang Technologies

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Tong Ren Tang Technologies Co. Ltd. is engaged in the manufacturing and sale of Chinese medicine products both in Mainland China and internationally, with a market cap of HK$6.24 billion.

Operations: The company's revenue is primarily generated from its operations, with CN¥4.46 billion attributed to its core business and CN¥1.47 billion from Tong Ren Tang Chinese Medicine.

Market Cap: HK$6.24B

Tong Ren Tang Technologies, with a market cap of HK$6.24 billion, has demonstrated stable financial footing despite recent challenges. The company reported full-year sales of CN¥7.26 billion, an increase from the previous year, yet net income declined to CN¥521.8 million from CN¥590.19 million due to lower profit margins and negative earnings growth over the past year. While its short-term assets exceed liabilities and it maintains more cash than total debt, management's inexperience may pose risks. The company proposed a final dividend of RMB 0.18 per share for 2024, reflecting consistent shareholder returns amidst volatility concerns.

Click here and access our complete financial health analysis report to understand the dynamics of Tong Ren Tang Technologies. Understand Tong Ren Tang Technologies' earnings outlook by examining our growth report.SEHK:1666 Financial Position Analysis as at Apr 2025

Alibaba Health Information Technology

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Alibaba Health Information Technology Limited operates in pharmaceutical direct sales, e-commerce platforms, and healthcare and digital services in Mainland China and Hong Kong, with a market cap of approximately HK$76.55 billion.

Operations: The company generates revenue of CN¥28.34 billion from its distribution and development of pharmaceutical and healthcare business segment.

Market Cap: HK$76.55B

Alibaba Health Information Technology, with a market cap of HK$76.55 billion, operates in pharmaceutical direct sales and healthcare services across Mainland China and Hong Kong. The company is debt-free, with short-term assets (CN¥11.9 billion) comfortably exceeding both short-term (CN¥4.9 billion) and long-term liabilities (CN¥149.2 million). Earnings have grown significantly over the past five years but recently faced a large one-off loss of CN¥395.8 million impacting financial results to September 2024. Despite high volatility in its share price, earnings are forecast to grow by 19.44% annually, suggesting potential for future growth amidst current challenges.

Dive into the specifics of Alibaba Health Information Technology here with our thorough balance sheet health report. Examine Alibaba Health Information Technology's earnings growth report to understand how analysts expect it to perform.SEHK:241 Debt to Equity History and Analysis as at Apr 2025

Where To Now?

Dive into all 5,658 of the  Global Penny Stocks we have identified here. Searching for a Fresh Perspective? Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include SEHK:1448 SEHK:1666 and SEHK:241.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments